Skip to main content
. 2017 Nov 8;6(11):e006513. doi: 10.1161/JAHA.117.006513

Table 1.

Baseline Characteristics

Epirubicin=400 mg/m2 (n=27) Epirubicin <400 mg/m2 (n=94)
Age, y 51.0 (42.0, 59.0) 48.5 (43.8, 58.0)
Body mass index 24.5 (22.2, 27.2) 25.9 (22.9, 29.1)
Systolic blood pressure, mm Hg 135.0 (120.0, 140.0) 128.5 (120.0, 140.0)
Diastolic blood pressure, mm Hg 80.0 (75.0, 85.0) 80.0 (74.5, 85.0)
Heart rate, beats/min 71.5±10.3 70.9±10.0
Hypertension (n) 1 (7%) 7 (7.4%)
Diabetes mellitus (n) 0 (0%) 2 (2.1%)
Current smoking (n) 6 (22.2%) 19 (20.2%)
Serum creatinine, mg/dL 0.75 (0.69, 0.81) 0.72 (0.69, 0.81)
Hemoglobin, g/dL 13.2±0.94 13.3±0.81
FEC treatment
FEC 60 mg/m2×4 (n) 0 71 (75.5%)
FEC 60 mg/m2×6 (n) 0 23 (24.5%)
FEC 100 mg/m2×4 (n) 27 (100%) 0
HER2 status Positive Negative
Assigned to metoprolol and placebo (n) 6 23
Assigned to candesartan and placebo (n) 7 25
Assigned to metoprolol and candesartan (n) 7 23
Assigned to placebo and placebo (n) 7 23

Data are expressed as mean±SD, median (interquartile range) or numbers (percent). FEC indicates 5‐fluorouracil, epirubicin, cyclophosphamide; HER, human epidermal growth factor receptor.